Hindustan Antibiotics

Hindustan Antibiotics Limited, commonly abbreviated HAtL, is an Indian central public sector pharmaceutical undertaking headquartered at Pimpri in Pune, Maharashtra. It was established with a public-health mission: to manufacture medicines in India and make essential treatment more affordable and broadly available. The enterprise was created in cooperation with the World Health Organization and UNICEF and was inaugurated by India's first prime minister, Jawaharlal Nehru, on 10 March 1954. Manufacturing began in 1955. The company represented an important early step in the development of India's public pharmaceutical manufacturing capability. Its formation was associated with the idea that the country's poor should have access to medicines at affordable prices, an objective linked in the company's historical account to Mahatma Gandhi's social vision. As India's first government-owned drug manufacturer, Hindustan Antibiotics was intended not merely to sell a branded range of medicines but also to establish domestic capacity for producing important pharmaceutical ingredients and finished formulations. Its traditional focus has been anti-infective medicines. The company's internally developed or manufactured portfolio has included Hamycin, penicillin products, ampicillin sodium, benzathine penicillin under the Longacillin name, amoxycillin trihydrate under the Delamin name, cefuroxime sodium, cefotaxime sodium under the Haltax name, ceftriaxone sodium under the Haxone name, and meropenem under the Halpen name. The portfolio illustrates a progression from established antibiotic products to broader classes of modern antibacterial and specialty medicines. The company also developed Hemax, a recombinant human erythropoietin product, and is identified as the first Indian company to launch a recombinant-DNA product, in 1993. Hindustan Antibiotics later expanded beyond conventional human healthcare. Its activities came to include agricultural and veterinary products, including Aureofungin for antifungal preservation of fruits and vegetables, Humaur bio-organic foliar spray, Streptocycline for bacterial plant diseases, and soil or crop inputs marketed as Azotomeal and Phosphomeal. This diversification extended the enterprise's role from a conventional pharmaceutical manufacturer into adjacent biological, agricultural, and veterinary applications. The company operates or operated a manufacturing complex at Pimpri with facilities for bulk drugs and multiple dosage forms. The reference material describes annual capacities of approximately 60 million mega units for bulk drugs, 132 million injectable vials, 250 million capsules, 120 million tablets, 12 million large-volume parenteral bottles, as well as liquid oral products. These capabilities allowed it to manufacture both active pharmaceutical materials and finished medicines in forms used by hospitals, clinicians, pharmacies, and public-health programs. Hindustan Antibiotics encountered serious financial difficulty after reporting an operating loss in 1997 and was referred to India's Board for Industrial and Financial Reconstruction. The company was subsequently removed from the BIFR process on 17 January 2009 after reporting a record turnover of ₹120 crore for the period cited in the reference material. Around the same period, it introduced products including Halpen, Haltax, and Hexpan in 2008 and announced plans for production of Sati-HIV medicines from September 2009. The available material documents these milestones but does not establish the company's current financial condition, product availability, or operating status.

Hindustan Antibiotics was established in India in 1954 as a public pharmaceutical manufacturing enterprise. Its creation was supported by cooperation with the World Health Organization and UNICEF, reflecting an effort to build domestic production of medicines while pursuing the social objective of making treatment affordable and available across the country. The company was inaugurated by Prime Minister Jawaharlal Nehru at Pimpri near Pune on 10 March 1954, and production commenced in 1955. The enterprise occupied a distinctive place in India's industrial and healthcare history because it was the country's first government-owned drug manufacturer. Its mandate combined industrial development with public health. Rather than relying exclusively on imported medicines, the company was intended to produce pharmaceutical ingredients and formulations within India. Its historical mission was associated with the principle that poor people should be able to obtain medicines at affordable prices, a principle linked in the supplied account to Mahatma Gandhi's vision. Hindustan Antibiotics developed a substantial anti-infective portfolio. Products included Hamycin, a company research product; several penicillin preparations; ampicillin sodium; benzathine penicillin sold as Longacillin; amoxycillin trihydrate sold as Delamin; cefuroxime sodium; cefotaxime sodium sold as Haltax; ceftriaxone sodium sold as Haxone; and meropenem sold as Halpen. The range covered both established antibiotic therapies and newer antibacterial classes. The company also entered recombinant biotechnology. In 1993 it launched Hemax, a recombinant human erythropoietin product, described in the reference material as the first recombinant-DNA product launched in India. The company's scope later broadened into agricultural and veterinary applications. Its listed products included Aureofungin, an antifungal product used in the preservation of fruits and vegetables; Humaur, a bio-organic foliar spray; Streptocycline, used to control bacterial diseases in plants; and the agricultural inputs Azotomeal and Phosphomeal. This diversification connected its pharmaceutical manufacturing expertise with crop protection, agricultural biologicals, and veterinary-related markets. The Pimpri manufacturing plant was described as having facilities for bulk drugs and numerous finished dosage forms. Reported annual capacities included 60 million mega units of bulk drugs, 132 million injectable vials, 250 million capsules, 120 million tablets, 12 million large-volume parenteral bottles, and production capability for liquid oral medicines. These facilities gave the company the ability to manufacture active materials and finished formulations for institutional and commercial use. Financial pressure became a major part of the company's later history. After reporting an operating loss in 1997, Hindustan Antibiotics was referred to the Board for Industrial and Financial Reconstruction, India's mechanism for dealing with financially distressed industrial enterprises. The company was reported to have improved sufficiently to be removed from the BIFR books on 17 January 2009, following a record turnover of ₹120 crore in the period cited by the reference material. Around this time, it introduced Halpen, Haltax, and Hexpan in 2008 and planned production of Sati-HIV medicines beginning in September 2009. Hindustan Antibiotics remains identified in the supplied reference as a central public sector undertaking under the Ministry of Chemicals and Fertilizers of the Government of India. The available source material does not provide enough current information to determine its present operating status, current leadership, active product catalogue, financial performance, or distribution footprint. Its documented historical significance lies in the combination of state ownership, early domestic antibiotic manufacturing, affordable-medicine objectives, and pioneering participation in India's recombinant pharmaceutical production.

• 2009

  Removal from BIFR records

  [1]Hindustan Antibioticsen.wikipedia.org

  Hindustan Antibiotics was removed from the BIFR books on 17 January after reporting the record turnover cited in the reference material.

• 2008

  New product introductions

  [1]Hindustan Antibioticsen.wikipedia.org

  The company introduced Halpen, Haltax, and Hexpan.

• 1997

  Referral to BIFR

  [1]Hindustan Antibioticsen.wikipedia.org

  The company was reported to the Board for Industrial and Financial Reconstruction after recording an operating loss.

• 1993

  Hemax recombinant erythropoietin launch

  [1]Hindustan Antibioticsen.wikipedia.org

  Hindustan Antibiotics launched Hemax, a recombinant human erythropoietin product identified as India's first recombinant-DNA product launch.

• 1955

  Production begins

  [1]Hindustan Antibioticsen.wikipedia.org

  The company commenced pharmaceutical production as India's first government-owned drug manufacturer.

• 1954

  Company inaugurated

  [1]Hindustan Antibioticsen.wikipedia.org

  Hindustan Antibiotics was inaugurated at Pimpri near Pune on 10 March by Prime Minister Jawaharlal Nehru, following cooperation involving WHO and UNICEF.

A government-owned Indian pharmaceutical manufacturer focused historically on affordable anti-infective medicines, domestic production capacity, and public-health supply, with additional activity in recombinant biotechnology, agriculture, and veterinary products.

• Antifungal medicine

  Hamycin

  Hamycin is identified as a product developed through Hindustan Antibiotics' own research. It belongs to the company's historical healthcare portfolio and represents its role in developing and manufacturing anti-infective medicines rather than only distributing products sourced from elsewhere.

• Penicillin antibiotic

  Longacillin

  Longacillin is the company's branded benzathine penicillin offering. It is part of the penicillin family within Hindustan Antibiotics' traditional anti-infective portfolio, alongside benzyl penicillin potassium, benzyl penicillin sodium, and other antibiotic preparations.

• Penicillin antibiotic

  Delamin

  Delamin is the brand name associated with amoxycillin trihydrate in the supplied product list. It illustrates the company's manufacture of widely used antibacterial medicines in finished pharmaceutical form for the Indian healthcare market.

• Cephalosporin antibiotic · 2008

  Haltax

  Haltax is the company's branded cefotaxime sodium product. It was among the products specifically reported as introduced in 2008, placing it within a later generation of the company's antibacterial portfolio and its effort to expand beyond older penicillin products.

• Cephalosporin antibiotic

  Haxone

  Haxone is the listed brand for ceftriaxone sodium. The product formed part of Hindustan Antibiotics' injectable and anti-infective manufacturing capabilities, although the available reference does not specify its launch date, current availability, or principal clinical markets.

• Carbapenem antibiotic · 2008

  Halpen

  Halpen is the brand associated with meropenem and was one of the new products reported as introduced in 2008. Its inclusion demonstrates the company's movement into advanced antibacterial products in addition to its historical penicillin and cephalosporin lines.

• Recombinant biotechnology medicine · 1993

  Hemax

  Hemax is a recombinant human erythropoietin product launched by Hindustan Antibiotics in 1993. The reference material describes it as the first recombinant-DNA product launched in India, making it a significant technology milestone beyond the company's traditional antibiotic business.

• Agricultural antifungal product

  Aureofungin

  Aureofungin is listed among the company's agricultural products. It is described as an antifungal application used in the preservation of fruits and vegetables, showing Hindustan Antibiotics' diversification into crop-related and post-harvest uses.

• Agricultural antibacterial product

  Streptocycline

  Streptocycline is an agricultural antibacterial product identified for controlling diseases in plants. It belongs to the company's non-human-health portfolio, which extended its manufacturing and biological-product activities into agriculture.

• 2009

  Planned entry into Sati-HIV medicine productionStrategy

  Background

  The company was reported to be broadening its healthcare manufacturing activity into HIV medicines.

  Action taken

  Production of Sati-HIV drugs was planned to begin in September 2009.

  Aftermath

  The supplied material does not document whether the planned production continued or its subsequent commercial outcome.

  Source

• 2009

  Exit from the BIFR processOther

  Background

  Hindustan Antibiotics had been referred to the Board for Industrial and Financial Reconstruction after an operating loss reported in 1997.

  Action taken

  The company was removed from the BIFR books on 17 January 2009 after reporting the record turnover cited by the reference.

  Aftermath

  The source records the removal but does not provide enough information to assess the company's later financial sustainability.

  Turnover. ₹120 crore (Reported as a record turnover by 17 January 2009; exact accounting period unspecified)

  Source

• 2008

  Expansion of the anti-infective portfolioProduct launch

  Background

  The company introduced Halpen, Haltax, and Hexpan in 2008 while continuing its role as a public pharmaceutical manufacturer.

  Action taken

  Hindustan Antibiotics launched or introduced the three named products.

  Aftermath

  The available reference does not provide subsequent sales, market-share, or product-availability results.

  Source

1. 1Hindustan Antibioticsen.wikipedia.org